Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- FY2023 Logs Gyration in COVID Drug Sales, Stark Contrast for Ronapreve, Lagevrio
July 11, 2024
- Taiho Bags Japan, Asian Rights to Arcus’ CD73 Inhibitor
July 10, 2024
- Mitsubishi Tanabe to Copromote Moderna’s mRNA Respiratory Vaccines
July 10, 2024
- Mounjaro Winner in May GP Rep Promotion Rankings: Intage
July 9, 2024
- Moderna Medical Chief Voices Excitement for Flu-COVID Jab; Japan PIII Set to Kick Off by Year’s End
July 9, 2024
- Shionogi Rolls Out In Vitro Diagnostic for Fetroja in Japan
July 9, 2024
- Rapalimus Granules Now Available in Japan: Nobelpharma
July 9, 2024
- FunPep to Run Additional Trial for Functional Peptide in Skin Ulcers
July 8, 2024
- Japan Ethical Drug Sales Up 4.9% in May: Crecon
July 8, 2024
- Viatris Begins Japan PIII for IgA Nephropathy Drug
July 5, 2024
- Keytruda Best-Selling Drug in Japan for 9 Months Running: Encise
July 5, 2024
- 32 Pharma Execs Snag 100 Million Yen-Plus in FY2023, Takeda Sweeps Top 3
July 4, 2024
- TMS Gets Rights to Hokkaido University’s Spinal Cord Injury Therapy
July 4, 2024
- Blackstone to Sell Alinamin to MBK Partners
July 4, 2024
- Chugai Grabs Japan’s Best-Paying Pharma Crown Yet Again: Jiho Tally
July 3, 2024
- Mochida Files EPA Agent Epadel in China
July 3, 2024
- China Approves Xtandi for Metastatic Hormone-Sensitive Prostate Cancer: Astellas
July 3, 2024
- Janssen Rebranded as J&J in Japan as Part of Global Move
July 2, 2024
- Medipal/JCR’s MPS IIIB Drug Now in Line to Enter Clinic
July 2, 2024
- MSD to Transfer Belsomra Distribution Rights to Daiichi Sankyo in Japan
July 2, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…